Generation and Characterization of Adeno-Associated Virus Producer Cell Lines for Research and Preclinical Vector Production
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) producer cell lines represent an effective method for large-scale production of AAV vectors. We set out to evaluate and characterize the use of an abbreviated protocol to generate "masterwells" (MWs; a nonclonal cell population) as a platform for research and preclinical vector production. In this system, a single plasmid containing three components, the vector sequence, the AAV rep, and cap genes, and a selectable marker gene is stably transfected into HeLaS3 cells. Producer cell lines generating an AAV2 vector expressing a secreted form of human placental alkaline phosphatase (SEAP) have been created. Several MWs showed vector yields in the 5×10(4) to 2×10(5) DNase-resistant particles/cell range, and the productivity was stable over >60 population doublings. Integrated plasmid copy number in three high-producing MWs ranged from approximately 12 to 50; copies were arranged in a head-to-tail configuration. Upon infection with adenovirus, rep/cap copy number was amplified approximately 100-fold and high yield appeared to be dependent on the extent of amplification. Rep/cap gene expression and vector packaging both reached a peak at 48 hr postinfection. AAV2-SEAP vector was produced in 1-liter shaker culture and purified for assessment of vector quality and potency. The data showed that the majority of the capsids from the MWs contained vector DNA (≥70%) and that purified vector was free of replication-competent AAV. In vitro and in vivo analyses demonstrated that potency of the producer cell-derived vector was comparable to vector generated via the standard transfection method.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“…2012) in addition to promising results in trials for Leber’s congenital amaurosis (Bainbridge et al. , 2008; Cideciyan et al. , 2008, 2009a,b; Maguire et al. , 2008, 2009; Simonelli et al. , 2010) and hemophilia B (Nathwani et al. , 2011) has served to further validate the potential for…”
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 2×
“…for the treat-ment of lipoprotein lipase deficiency (Yla-Herttuala, 2012) in addition to promising results in trials for Leber’s congenital amaurosis (Bainbridge et al. , 2008; Cideciyan et al. , 2008, 2009a,b; Maguire et al. , 2008, 2009; Simonelli et al. , 2010) and hemophilia B (Nathwani et al.…”
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 1×
“…in trials for Leber’s congenital amaurosis (Bainbridge et al. , 2008; Cideciyan et al. , 2008, 2009a,b; Maguire et al. , 2008, 2009; Simonelli et al. , 2010) and hemophilia B (Nathwani et al. , 2011) has served to further validate the potential for clinical application of rAAV-based gene therapies.”
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865 · cited 1×
“…2012) in addition to promising results in trials for Leber’s congenital amaurosis (Bainbridge et al. , 2008; Cideciyan et al. , 2008, 2009a,b; Maguire et al. , 2008, 2009; Simonelli et al. , 2010) and hemophilia B (Nathwani et al. , 2011) has served to further validate the potential for…”
Grimm, D., Kern, A., Pawlita, M., Ferrari, F. K., Samulski, R. J., & Kleinschmidt, J. A. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300946 · Cited by 195 · cited 2×
“Indeed, the former more closely approximates the ratio of total viral particles to DNA-containing particles observed for wtAAV (Grimm et al. , 1999; Zeltner et al. , 2010).”
Allay, J. A., Sleep, S., Long, S., Tillman, D. M., Clark, R., Carney, G., Fagone, P., McIntosh, J. H., Nienhuis, A. W., Davidoff, A. M., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.202 · Cited by 152 · cited 1×
“However, they are substantially higher than 0.02%, the quantity of encapsidated cap DNA present in AAV-hFIX clinical vectors produced by transfection (Hauck et al. , 2009; Allay et al. , 2011).”
InfluentialProduction, purification and characterization of adeno-associated vectors
Ayuso, E., Mingozzi, F., & Bosch, F. (2010) · Current Gene Therapy · doi:10.2174/156652310793797685 · Cited by 151 · cited 1×
“At the present time, clinical-grade rAAV is generated at large-scale via the helper virus-free transient transfection method, the recombinant baculovirus or herpes simplex virus-based production systems, or packaging/producer cell lines (reviewed by Ayuso et al. , 2010).”
Wistuba, A., Weger, S., Kern, A., & Kleinschmidt, J. A. (1995) · Journal of Virology · doi:10.1128/jvi.69.9.5311-5319.1995 · Cited by 147 · cited 2×
“Interestingly, the Rep protein profile differs from that observed in wtAd and wtAAV2 co-infected HeLa cells (Wistuba et al. , 1995).”
Transient transfection methods for clinical adeno-associated viral vector production
Wright, J. F. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.064 · Cited by 131 · cited 2×
“…has been produced via the standard transfection method in which HEK293 cells are co-transfected with two or three plasmids encoding the cis (vector genome) and trans (AAV rep and cap genes; adenoviral helper genes E2A, E4, and VA ) elements required for vector packaging (reviewed by Wright, 2009).”
Hauck, B., Murphy, S. L., Smith, P. H., Qu, G., Liu, X., Zelenaia, O., Mingozzi, F., Sommer, J. M., High, K. A., & Wright, J. F. (2009) · Molecular Therapy · doi:10.1038/mt.2008.227 · Cited by 88 · cited 2×
“However, they are substantially higher than 0.02%, the quantity of encapsidated cap DNA present in AAV-hFIX clinical vectors produced by transfection (Hauck et al. , 2009; Allay et al. , 2011).”
Influential
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Manufacturing of recombinant adeno-associated viral vectors for clinical trials
Clément, N., & Grieger, J. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.2 · Cited by 286
Manufacturing challenges and rational formulation development for AAV viral vectors
Srivastava, A., Mallela, K. M. G., Deorkar, N., & Brophy, G. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.03.024 · Cited by 269
Pharmacology of Recombinant Adeno-associated Virus Production
Penaud-Budloo, M., François, A., Clément, N., & Ayuso, E. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.002 · Cited by 177
“2%–1%.(56,70) In these cases, antibiotic resistance could come from the rep-cap plasmid or the plasmid harboring rAAV genome that were used to stably integrate the corresponding sequences in the cell genome.”
BackgroundInfluentialBurnham, B., Nass, S., Kong, E., Mattingly, M., Woodcock, D., Song, A., Wadsworth, S., Cheng, S. H., Scaria, A., & O'Riordan, C. R. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.048 · Cited by 150
“35,37 Briefly, a HeLa-based producer cell line was created following transfection of HeLaS3 cells (ATCC CCL-2.”
Self-citation
Metadata
- Authors
- Martin, J., Frederick, A., Luo, Y., Jackson, R., Joubert, M., Sol, B., Poulin, F., Pastor, E., Armentano, D., Wadsworth, S., & Vincent, K.
- Venue
- Human Gene Therapy Methods
- Publisher
- SAGE Publications
- Published
- 2013-08
- Volume
- 24
- Issue
- 4
- Pages
- 253-269
- ISSN
- 1946-6536 (ISSN-L)
- 1946-6544
- OpenAlex
- W2060038854
- Cited by
- 79
- References
- 10
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.